Giannoula Lakka Klement, MD, F.R.C.P.(C) is presently a senior investigator with the ICBP Center for Cancer System Biology at Tufts University, and a Director of the Newman-Lakka Institute for Personalized Cancer Care at Floating Hospital for Children at Tufts Medical Center. The Institute is the first of its kind to collect data on children and adults treated with metronomic chemotherapy in combination with molecularly targeted therapies. She is an Assistant Professor at Tufts University School of Medicine and a Clinician/Scientist at Floating Hospital for Children/ Tufts Medical Center, where is leads the Rare Tumors and Vascular Anomalies Center.
She received her MD in 1992 from McMaster University in Hamilton, Ontario in 1992. She did her pediatric residency and pediatric hematology oncology fellowship at the Hospital for Sick Children in Toronto, Canada from 1992-1997. She received National Cancer Institute of Canada Terry Fox Postgraduate Research Fellowship in 1997, and joined the laboratory of Dr. Robert Kerbel, at the Sunnybrook & Women’s College Health Sciences Center at University of Toronto to work on tumor angiogenesis. Her post–doctoral work led to early descriptions of the mechanism of action of low dose continuous chemotherapy, and the editorial to her publication first coined the term “metronomic chemotherapy”.
In 2003 Dr. Klement moved to Boston to join the research group of the late Dr. Judah Folkman at Harvard Medical School, Children’s Hospital Boston and Dana-Farber Cancer Institute. She developed a joined program of Clinical Experimental Therapeutics at the Vascular Anomalies Center at Children’s Hospital Boston/Dana-Farber Cancer Institute. Her basic science laboratory focused on developing sensitive biomarkers of therapeutic response. She discovered that the majority of angiogenesis regulators, both stimulators and inhibitors, are sequestered in platelets and can be detected in platelets very early in tumor growth.
Dr. Klement’s clinical and research interests come together in a single goal of developing minimally toxic therapies for cancer.